Natera Inc
NASDAQ:NTRA

Watchlist Manager
Natera Inc Logo
Natera Inc
NASDAQ:NTRA
Watchlist
Price: 168.32 USD 2.39% Market Closed
Market Cap: 20.8B USD
Have any thoughts about
Natera Inc?
Write Note

Gross Margin
Natera Inc

57.7%
Current
47%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
57.7%
=
Gross Profit
883.4m
/
Revenue
1.5B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Natera Inc
NASDAQ:NTRA
20.9B USD
58%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
67%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.3B EUR
89%
Country US
Market Cap 20.9B USD
Gross Margin
58%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.7B USD
Gross Margin
67%
Country US
Market Cap 147.4B USD
Gross Margin
60%
Country US
Market Cap 119.4B USD
Gross Margin
86%
Country US
Market Cap 113.8B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.4B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.3B EUR
Gross Margin
89%
No Stocks Found

Natera Inc
Glance View

Market Cap
20.9B USD
Industry
Biotechnology

Natera Inc. is a leading genomics company that specializes in genetic testing and precision medicine, aiming to revolutionize healthcare through advanced DNA analysis. Founded in 2004 and headquartered in Austin, Texas, Natera focuses on reproductive health, oncology, and organ transplant management, providing invaluable insights that help doctors make informed decisions for their patients. Its flagship products include non-invasive prenatal testing (NIPT), which has gained significant traction for its ability to assess fetal health with remarkable accuracy, along with tests for hereditary cancer risk and monitoring treatment response in cancer patients. By harnessing the power of next-generation sequencing and machine learning, Natera is positioned to disrupt traditional medical practices and improve patient outcomes. Investors looking at Natera will find a company poised for growth amid increasing demand for genetic testing and personalized medicine. The company benefits from a robust pipeline and an expanding customer base, bolstered by strategic collaborations with healthcare providers and insurance companies. As awareness of genetic testing continues to rise, Natera's innovative solutions could capture substantial market share, particularly in oncology, where early detection can dramatically impact treatment efficacy and survival rates. With strong financial backing, a commitment to research and development, and a vision to elevate the standard of care through data-driven insights, Natera represents a compelling opportunity for those seeking to invest in the future of healthcare.

NTRA Intrinsic Value
56.49 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
57.7%
=
Gross Profit
883.4m
/
Revenue
1.5B
What is the Gross Margin of Natera Inc?

Based on Natera Inc's most recent financial statements, the company has Gross Margin of 57.7%.